Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Breast Neoplasms 35Lymphoma, Large B-Cell, Diffuse 22Sarcoma 19Lymphoma 19Carcinoma, Hepatocellular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Non-Hodgkin 9Hodgkin Disease 9Multiple Myeloma 8Leukemia 8Neuroblastoma 6Liver Neoplasms 6Lymphoma, Follicular 5Immunoblastic Lymphadenopathy 5Ovarian Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Triple Negative Breast Neoplasms 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Neoplasms, Plasma Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Liposarcoma 3Leiomyosarcoma 3Chondrosarcoma 3Burkitt Lymphoma 3Wilms Tumor 2Rhabdomyosarcoma 2

Interventions

Doxorubicin 2lentiviral minigene vaccine of COVID-19 coronavirus 1camrelizumab 1apatinib 1Vinorelbine 1Methotrexate 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Neoplasms, Connective and Soft Tissue × Doxorubicin × Clear all
NCT05057130 2024-04-01

Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors

Blokhin's Russian Cancer Research Center

Phase 2/3 Unknown
50 enrolled
Sarcoma

Bone Neoplasms, Neoplasms, Connective Tissue, Sarcoma, Osteosarcoma, Neoplasms, Connective and Soft Tissue

NCT04910126 2021-06-02

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
84 enrolled
Sarcoma

Sarcoma, Neoplasms, Connective and Soft Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡